Myeloma Data Highlights; J&J Skips GLP-1 Race

Healthcare equities traded mixed as investors assessed late-stage clinical trial readouts against broader market pressures. UnitedHealth Group ($UNH) closed at $399.53, down 1.99%, while Amgen ($AMGN) settled at $341.66, declining 1.78%. Bristol Myers Squibb ($BMY) finished at $55.28, down 1.14% despite reporting positive Phase III data in multiple myeloma. Moderna ($MRNA) extended its winning streak to a fifth consecutive day, climbing 11.55% to $61.80 ahead of its Investor Day event.

Bristol Myers Squibb ($BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference, highlighting early clinical success for a new CAR T-cell therapy targeting blood cancers. The company appointed a new General Manager to lead its operations across the Gulf region. Analysts noted $BMY stock could be 12.2% undervalued based on pipeline and margin expectations, with one-year total shareholder return of 23.92% offsetting recent softness including 30-day and 90-day declines of 3.54% and 4.87%, respectively. Johnson & Johnson ($JNJ) reported Phase III results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple myeloma through the MonumenTAL-3 study, the first to show a GPRC5D bispecific antibody combination achieving improved outcomes versus standard regimens in earlier treatment lines. CEO Joaquin Duato stated $JNJ has no plans to enter the obesity drugs market, opting instead to focus on diseases such as cancer, setting the company apart from rivals developing or acquiring obesity medicines following blockbuster weight-loss drugs from Eli Lilly ($LLY) and Novo Nordisk.

Eli Lilly ($LLY) announced that Axcelead Drug Discovery Partners has entered a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by the company. On June 15, $LLY shared data from the Phase 1 AJX-101 study showing that an investigational type II JAK2 inhibitor delivered an encouraging safety profile, demonstrating clinical activity. Merck ($MRK) announced a multi-target AI drug discovery collaboration with Protillion Biosciences, focused on high-throughput protein engineering for new therapeutics, with the agreement including potential milestone payments tied to progress across multiple discovery programs. Pfizer ($PFE) is scheduled to participate in the ISG AI Impact Summit on June 22-23 in Frankfurt to discuss return on investment from AI initiatives.

Johnson & Johnson ($JNJ) announced plans to invest over $1 billion in a Florida contact lens manufacturing facility, expanding its presence in the vision care segment. With a net profit margin of 21.83%, $JNJ develops, manufactures, and sells a broad range of healthcare products across multiple areas of the industry. The company remains among the Dividend Kings, maintaining more than 50 years of steadily rising dividend payouts. The diagnostics market also saw activity, with the global Fluorescent In Situ Hybridization Probe market valued at approximately $1.14 billion in 2025, expected to reach $1.23 billion in 2026 and $2.27 billion by 2035 at a 7.9% CAGR, with key players including Thermo Fisher ($TMO).

ABIVAX plans to submit an NDA for obefazimod in Q4 2026, though its Crohn's disease Phase 2b data has been delayed to mid-2027. Merck ($MRK) launched a global HPV awareness initiative with Nivi, aimed at emerging markets with high cervical cancer burden, using digital and AI-powered health education tools to support HPV vaccination and screening efforts. The partnership targets regions where cervical cancer represents a significant public health challenge.

Moderna ($MRNA) is scheduled to host an Investor Day event following its extended rally, with investors anticipating updates on pipeline strategy and commercial outlook. ABIVAX expects to file its NDA for obefazimod in the fourth quarter of 2026, with mid-2027 timing for Phase 2b Crohn's disease data. Merck ($MRK) and Eli Lilly ($LLY) continue to advance AI-driven drug discovery collaborations that may yield future pipeline updates. Johnson & Johnson ($JNJ) targets becoming the number one oncology player by 2030, focusing on cancer and neuroscience rather than obesity treatments.